News

CorMedix Q1 revenue surges to $127.4M driven by DefenCath and Melinta sales, with organic growth outpacing TDAPA expiration concerns.

Eton Pharmaceuticals Q1 sales rose 73% driven by rare-disease portfolio expansion, with full-year guidance raised to $120 million.

Senti Biosciences advances CAR-NK program into pivotal AML trial with FDA RMAT designation and single-arm registrational pathway support.

Biogen completes Apellis Pharmaceuticals acquisition for $41 per share, gaining complement therapy assets and nephrology infrastructure for felzartamab launch.

Emrosi revenue tripled in Q1 2026 as Journey Medical reaches 85% payer coverage and achieves positive adjusted EBITDA.

Humacyte posts fivefold Symvess revenue growth in Q1 2026 while restructuring operations ahead of critical Phase 3 interim data.

Can-Fite advances namodenoson into Phase 2b study for pancreatic cancer, seeking a pharma partner to fund the combination trial...

Setmelanotide BMI Reduction reaches 19.6% at nine months in acquired hypothalamic obesity patients, with significant cardiometabolic improvements shown.

Kura Oncology reports Q1 2026 ziftomenib revenue of $5.8M with 85 new patient starts and repeat prescription signals in...

Boehringer Ingelheim licenses a preclinical antibody from Immunitas for inflammatory diseases, with milestone payments reaching €407.5 million.